First from left: Cheng Jinsheng, General Manager of Dongfulong Life Sciences Division

Right: Dr. Jin Jun, General Manager and CTO of Yuanvore Medicine

On the afternoon of December 11, 2024, Shanghai Yuanvore Medicine Technology Co., Ltd. and Dongfulong Technology Group Co., Ltd. held a strategic cooperation signing ceremony.

The two parties will focus on the entire life cycle of iPS cell GMP production, from the entire chain of cell collection and reception, testing, culture preparation, quality control, storage to treatment, and combine technical paths to customize and develop production processes, equipment and consumables to jointly explore the world's leading iPSC technology industrialization full-scenario solution, with large-scale production to empower the accessibility of clinical applications of iPS cell drugs!

Dr. Jin Jun, General Manager and CTO of Yuanvore Medicine, and Cheng Jinsheng, General Manager of Dongfulong Life Sciences Division, signed a strategic cooperation agreement on behalf of both parties. Ouyang Ping, founder and chairman of Yuanwu Medical, Zheng Xiaoyou, senior vice president of Dongfulong Group, and special guests Professor Yuan Baozhu, School of Life Science and Technology of Tongji University, Pan Liuyang, CEO of Translational Medicine Network and director of Xinyuan Translational Medicine Center, etc. witnessed this signing.

First from left: Professor Yuan Baozhu, School of Life Science and Technology, Tongji University

Second from left: Cheng Jinsheng, General Manager of Dongfulong Life Sciences Division

First from the right: Pan Liuyang, CEO of Translational Medicine Network and Director of Xinyuan Translational Medicine Center

Second from the right: Zhou Hengyi, Life Sciences Division of Dongfulong

With the continuous breakthroughs and innovations of cell technology, contemporary medicine is gradually shifting from traditional treatment models to the field of cell therapy. In the global arena of cell drugs, China is emerging rapidly. This is due to my country's complete industrial system connecting upstream and downstream, and to the persistence and perseverance of countless companies involved in the cell industry on the road of innovation.

As an early pharmaceutical equipment company in China, Dongfulong not only creates two systems of space containment solutions and product containment solutions for cell therapy drugs, but also focuses on providing a series of compliance from various aspects such as processes, instruments, consumables, etc. Comprehensive solutions to ensure the safety, efficiency and excellent quality of drug production, and meet customers 'needs at different stages of R & D, pilot and commercial production.

Yuanvore Medicine is a regenerative medicine company focusing on the development and application of iPSC(Induced Pluripotent Stem Cell) technology. Pluripotent stem cells are ideal seed cells for future cell therapy due to their huge differentiation potential. The company's current pipeline indications are Parkinson's disease and osteoarthritis, both of which have entered the pre-clinical animal testing stage, and CMC process development will soon be launched.

Ouyang Ping, founder and chairman of Yuanvore Medicine:

The biggest challenge for cell drugs is accessibility. One of the key elements to meet accessibility is standardized, standardized, intelligent and large-scale production. Dongfulong Group is a forward-looking global service provider upstream of the industrial chain. It has taken the lead in the localization of equipment and consumables, injecting strong momentum into the vigorous development of China's cell industry. Through this strategic cooperation, we will take advantage of Dongfulong's professional advantages to press the "fast forward button" for the process development and application of products, and accelerate the "acceleration" on the road of exploration and application of iPSC technology industrialization. We hope to provide patients with safe, efficient, and ready-to-use cell drugs that can be produced on a large scale as soon as possible.

Zheng Xiaoyou, Senior Vice President of Dongfulong Group:

At present, there are only a handful of companies at home and abroad focusing on iPSC technology. Yuanvore Medicine has demonstrated unique technological advantages and innovation potential in this field, and has a leading advantage with Dongfulong in the field of one-stop overall solutions for cell therapy equipment and instruments., will form a strong complement. Driven by cutting-edge technology and guaranteed by stable quality, we will work together to actively promote the leapfrog development of Yuanwu Medical iPSC drug production process through sincere cooperation between the two parties and jointly open up a new chapter in regenerative medicine.

Stand at a new starting point, seize new opportunities, carry out new cooperation, and achieve new leaps. This cooperation empowers two-way and win-win cooperation, transforming the "key variable" of scientific and technological innovation into the "maximum increment" of high-quality development, becoming the leader in the industry, and demonstrating the determination and confidence of "professional technology to serve biomedicine". Let us look forward to cutting-edge cell therapy technology represented by iPSC bringing transformative therapies to patients with chronic degenerative diseases around the world and contributing to the cause of human health!